Bioheart Inc., of Sunrise, Fla., reported three-month follow-up data with stem cell therapy on the first two congestive heart failure patients showing that the first improved his walking distance on the six-minute walk test from 315 meters to 420 meters and had improved left ventricular ejection fraction (LVEF) from 32 percent to 38 percent...Bioheart's therapy involves the use of stem cells derived from the patient's own adipose tissue that are separated and later injected into the heart using the
Genmab A/S, of Copenhagen, Denmark, reported negative top-line interim results from an initial Phase II single-arm open-label study of ofatumumab to evaluate the treatment of relapsed diffuse large B-cell lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant
Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, reported results showing that its heart failure stem cell therapy C-Cure showed positive and encouraging trends in a number of physiological and clinical parameters, including meaningful differences in ventricular size, ejection fraction and other measures of heart muscle activity in C-Cure-treated patients when compared to control and to baseline
Stem Cell Therapeutics Corp., of Calgary, Alberta, disclosed top-line results for the modified REGENESIS-Phase IIb stroke trial, a placebo-controlled, double-blind, 3: 1 randomized study that enrolled 96 patients with acute ischemic stroke between August 2009 and Jan. 24, 2010
The four-patient study established that it was safe and feasible to transfect the lentiviral vector into human stem cells and for the RNA molecules to persist in the immune cells of patients undergoing autologous stem cell transplantation for AIDS-related lymphoma
The study showed a 21 percent improvement in overall survival for all patients who received Pixuvri that was independent of factors known to influence survival such as prior Rituxan (rituximab, Genentech Inc./Roche AG and Biogen Idec Inc.) use, international prognostic index score, prior stem cell transplant, baseline level of LDH or refractory status based on univariate Cox regression analyses of survival
Neuralstem Inc., of Rockville, Md., said the safety monitoring board approved moving to the next cohort of patients in the Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis...The first cohort of patients received five injections of the stem cells, while the second cohort of three patients will receive 10 injections, five on each side of the cord
Mesoblast Ltd., of Melbourne, Australia, received FDA clearance to start Phase II testing of its allogeneic stem cell product NeoFuse for fusion of the cervical spine in the neck
Stem Cell Therapeutics Corp., of Calgary, Alberta, said the 90-day follow up period for the last patient enrolled in the modified REGENESIS Phase IIb stroke trial has been reached
StemCells Inc., of Palo Alto, Calif., has submitted a protocol to the FDA for initiation of a second clinical trial of HuCNS-SC human neural stem cells in neuronal ceroid lipofuscinosis, also referred to as Batten disease
Stemedica Cell Technologies Inc., of San Diego, said the FDA approved an investigational new drug application for clinical testing of its allogeneic mesenchymal bone marrow-derived stem cells in ischemic stroke patients
Stem cells were separated from the adipose tissue utilizing the fully automated TGI 1200 Cell Isolation System...The recovered stem cells were injected into the patients' hearts utilizing Bioheart's MyoCath needle injection catheter
Stem Cell Therapeutics Corp., of Calgary, Alberta, closed patient enrollment in its modified Phase IIb stroke trial of NTx-265 and plans to analyze the data as they become available for the 96 patients using a modified statistical approach
Gentium SpA, of Villa Guardia, Italy, presented final results of a Phase II/III study showing that prophylactic use of Defibrotide in pediatric stem cell transplant patients at high risk for veno-occlusive disease demonstrated a 40 percent reduction in the incidence of VOD within 30 days after transplant according to intent-to-treat analysis of 356 patients
In a paper published in Blood, GVAX AML (immunotherapy) accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation in hematologic malignancies showed an overall survival rate in all subjects of 57.4 percent and 73.4 percent in the GVAX-treated group
Stem Cell Therapeutics Corp., of Calgary, Alberta, said Phase IIa data showed that stroke drug NTx-265 was found to be safe, with patients showing improved clinical outcomes compared to published data on similar untreated stroke patients, as well as a trend toward reduced infarct volumes over time in comparison to data previously described elsewhere
Chimerix Inc., of Research Triangle Park, N.C., started a Phase II trial to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus
Osiris Therapeutics Inc., of Columbia, Md., said data were presented at the 2010 BMT Tandem Meeting from a 59-patient study of stem cell product Prochymal in treatment-resistant pediatric graft vs
Athersys Inc., of Cleveland, completed patient enrollment for its Phase I trial of MultiStem, an allogeneic stem cell therapy administered to individuals following acute myocardial infarction...Stem Cell Therapeutics Corp., of Calgary, Alberta, said it will focus the remaining patient enrollment for its modified Phase IIb stroke trial in Canada and the U.S
Bioheart Inc., of Sunrise, Fla., reported three-month follow-up data with stem cell therapy on the first two congestive heart failure patients showing that the first improved his walking distance on the six-minute walk test from 315 meters to 420 meters and had improved left ventricular ejection fraction (LVEF) from 32 percent to 38 percent...Bioheart's therapy involves the use of stem cells derived from the patient's own adipose tissue that are separated and later injected into the heart using the